Adicet Bio Valuation
| ACET Stock | USD 0.78 0.01 1.27% |
Adicet Bio is undervalued. Adicet Bio shows a prevailing Real Value of $2.17 per share. The current price of the firm is $0.78. Our model approximates the value of Adicet Bio from analyzing the firm fundamentals such as Current Valuation of (93.42 M), return on equity of -0.58, and Shares Owned By Insiders of 2.75 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Adicet Bio's price fluctuation is very risky at this time. Calculation of the real value of Adicet Bio is based on 3 months time horizon. Increasing Adicet Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Adicet Bio's intrinsic value may or may not be the same as its current market price of 0.78, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.78 | Real 2.17 | Hype 0.78 |
The intrinsic value of Adicet Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adicet Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Adicet Bio helps investors to forecast how Adicet stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adicet Bio more accurately as focusing exclusively on Adicet Bio's fundamentals will not take into account other important factors: Adicet Bio Total Value Analysis
Adicet Bio is presently forecasted to have valuation of (93.42 M) with market capitalization of 64.16 M, debt of 17.23 M, and cash on hands of 260.64 M. The negative valuation of Adicet Bio may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Adicet Bio fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(93.42 M) | 64.16 M | 17.23 M | 260.64 M |
Adicet Bio Asset Utilization
One of the ways to look at asset utilization of Adicet is to check how much profit was generated for every dollar of assets it reports. Adicet Bio shows a negative utilization of assets of -0.33 percent, losing $0.00335 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Adicet Bio shows how discouraging it operates for each dollar spent on its assets.Adicet Bio Ownership Allocation
Adicet Bio holds a total of 82.69 Million outstanding shares. Over half of Adicet Bio's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Adicet Bio Profitability Analysis
Net Loss for the year was (117.12 M) with profit before overhead, payroll, taxes, and interest of 24.99 M.About Adicet Bio Valuation
The stock valuation mechanism determines Adicet Bio's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Adicet Bio based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adicet Bio. We calculate exposure to Adicet Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adicet Bio's related companies.Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people.
Adicet Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Adicet Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 87.9 M |
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.